MedTrace Logo

Risperidone Plus Mood Stabilizer in Treatment of Mixed Mania

NCT00294255 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2018-06-14

No results posted yet for this study

Summary

The study aims to assess the efficacy and tolerability of risperidone added to lithium, valproate or lamotrigine in patients experiencing a manic episode with depressive or irritable features.

Conditions

Interventions

DRUG

Risperidone

risperidone will be administered 1-3mg pills, each night, for up to 20 weeks

Sponsors & Collaborators

  • Janssen, LP

    collaborator INDUSTRY

  • The University of Texas Health Science Center at San Antonio

    lead OTHER

Principal Investigators

  • Vivek Singh, MD · UT-SanAntonio

  • Charles Bowden, MD · UT San Antonio

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-03-31
Primary Completion
2006-10-31
Completion
2006-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00294255 on ClinicalTrials.gov